Journal article

A biological perspective toward the interaction of theranostic nanoparticles with the bloodstream – what needs to be considered?

  • Clift, Martin J. D. BioNanomaterials, Adolphe Merkle Institute, University of Fribourg, Switzerland
  • Dechézelles, Jean-François BioNanomaterials, Adolphe Merkle Institute, University of Fribourg, Switzerland
  • Rothen-Rutishauser, Barbara BioNanomaterials, Adolphe Merkle Institute, University of Fribourg, Switzerland
  • Petri-Fink, Alke BioNanomaterials, Adolphe Merkle Institute, University of Fribourg, Switzerland - Department of Chemistry, University of Fribourg, Switzerland
Show more…
    2015
Published in:
  • Chemical Engineering. - 2015, vol. 3, p. 7
English Nanomedicine intends to create and further use novel materials at the nanoscale in order to provide an improvement upon current medical applications for human healthcare (ESF, 2005; Etheridge et al., 2013). In line with the advances made within nanotechnology since the late twentieth century (Mamalis, 2007) nanomedicine has received heightened attention due to its potential advantages, most notably within (cancer) theranostics (Muthu et al., 2014). The field of theranostics aims to utilize the physico-chemical characteristics of nanosized materials in order to intensify the effectiveness in diagnosing and treating diseases at the molecular level (Kim et al., 2013). Such a perspective is notably paramount for cancer types that are difficult to identify as well as apply therapy toward (e.g., secondary cancer) (Muthu et al., 2014).Despite the well documented and proposed benefits of therapeutics in the nano-size range (Krol et al., 2013), for the majority of nanoparticles (NPs) [defined as “a nano-object with all three dimensions in the nanoscale (1–100 nm)″ (BSI, 2007; ISO 27687, 2008)], the ability to merge the expansive divide between developing a significant advancement within material science and creating a biologically relevant therapeutic has proven to be a highly non-trivial task. One important reason for this is the relatively limited specific understanding of the biological interaction of therapeutic NPs following their administration into the human body and their subsequent delivery to the target site (e.g., tumor) (Capco and Chen, 2014). The objective of this opinion article therefore, is to provide a biological perspective upon what must be considered in the development of theranostic NPs.
Faculty
Faculté des sciences et de médecine
Department
Département de Chimie
Language
  • English
Classification
Biology
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/304203
Statistics

Document views: 3 File downloads:
  • pet_bpt.pdf: 3